Paper Details

  1. Home
  2. Paper Details

Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.

Author: BarriereSteven L, BentonBret M, GoldbergMichael R, GotfriedMark H, KittMichael M, KrauseKevin M, ShawJeng-Pyng

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study showed that telavancin, a new bactericidal lipoglycopeptide, penetrated well into the pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AMs) in healthy subjects. The concentrations found in ELF and AMs were significantly higher than the MIC90 for methicillin-resistant Staphylococcus aureus (MRSA), suggesting that telavancin could be a promising treatment option for gram-positive respiratory infections.
Paper Details　
Original Abstract of the Article :
Steady-state concentrations of telavancin, a novel, bactericidal lipoglycopeptide, were determined in the plasma, pulmonary epithelial lining fluid (ELF), and alveolar macrophages (AMs) of 20 healthy subjects. Telavancin at 10 mg of drug/kg of body weight/day was administered as a 1-h intravenous in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223919/

データ提供：米国国立医学図書館（NLM）

Telavancin: A New Weapon in the Desert of Gram-Positive Infections

This study ventures into the challenging terrain of bacterial infections, focusing on the potential of telavancin, a new type of antibiotic, to fight gram-positive infections. The authors are seeking to understand how telavancin works within the lungs, a crucial battlefield in the fight against respiratory infections.

Telavancin: Reaching the Oasis of Infection

The study found that telavancin effectively reached the site of infection in the lungs, achieving high concentrations in both the pulmonary epithelial lining fluid and alveolar macrophages. This suggests that telavancin could be a potent weapon against gram-positive respiratory infections. The study also found that telavancin was well tolerated by the participants, highlighting its potential as a safe and effective treatment option.

Navigating the Desert of Infections: Seeking Effective Treatments

This study offers a glimmer of hope in the desert of antibiotic resistance, suggesting that telavancin could be a valuable tool for fighting gram-positive infections. It emphasizes the need for continued research to evaluate the full potential of telavancin in clinical settings.

Dr. Camel's Conclusion

This study presents a compelling case for telavancin as a potential oasis of relief in the desert of gram-positive infections. Further research is needed to confirm its effectiveness and ensure its safe and appropriate use in clinical practice.
Date :
  1. Date Completed 2008-05-06
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

17923490

DOI: Digital Object Identifier

PMC2223919

Related Literature

Article Analysis
・Effects of telavancin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.